X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs IPCA LABS - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE IPCA LABS STRIDES PHARMA SCIENCE/
IPCA LABS
 
P/E (TTM) x 51.5 29.6 174.0% View Chart
P/BV x 1.1 3.8 29.8% View Chart
Dividend Yield % 0.4 0.1 347.8%  

Financials

 STRIDES PHARMA SCIENCE   IPCA LABS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
IPCA LABS
Mar-18
STRIDES PHARMA SCIENCE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,147695 164.9%   
Low Rs642400 160.5%   
Sales per share (Unadj.) Rs317.2260.2 121.9%  
Earnings per share (Unadj.) Rs7.819.0 41.3%  
Cash flow per share (Unadj.) Rs25.133.1 75.8%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.2 122.5%  
Book value per share (Unadj.) Rs274.3213.0 128.7%  
Shares outstanding (eoy) m89.50126.20 70.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.1 133.9%   
Avg P/E ratio x114.028.9 395.0%  
P/CF ratio (eoy) x35.716.6 215.5%  
Price / Book Value ratio x3.32.6 126.9%  
Dividend payout %25.55.3 483.7%   
Avg Mkt Cap Rs m80,05869,120 115.8%   
No. of employees `0002.513.3 18.9%   
Total wages/salary Rs m4,3417,359 59.0%   
Avg. sales/employee Rs Th11,325.82,477.4 457.2%   
Avg. wages/employee Rs Th1,731.4555.2 311.8%   
Avg. net profit/employee Rs Th280.1180.6 155.0%   
INCOME DATA
Net Sales Rs m28,39432,836 86.5%  
Other income Rs m941418 225.0%   
Total revenues Rs m29,33433,254 88.2%   
Gross profit Rs m3,9654,505 88.0%  
Depreciation Rs m1,5401,777 86.7%   
Interest Rs m1,962240 817.0%   
Profit before tax Rs m1,4032,905 48.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97511 19.0%   
Profit after tax Rs m7022,394 29.3%  
Gross profit margin %14.013.7 101.8%  
Effective tax rate %6.917.6 39.4%   
Net profit margin %2.57.3 33.9%  
BALANCE SHEET DATA
Current assets Rs m24,83619,455 127.7%   
Current liabilities Rs m18,99310,076 188.5%   
Net working cap to sales %20.628.6 72.0%  
Current ratio x1.31.9 67.7%  
Inventory Days Days7198 72.5%  
Debtors Days Days11367 169.4%  
Net fixed assets Rs m34,28920,260 169.2%   
Share capital Rs m895252 354.6%   
"Free" reserves Rs m23,65126,633 88.8%   
Net worth Rs m24,54626,886 91.3%   
Long term debt Rs m15,5132,340 662.9%   
Total assets Rs m65,43741,173 158.9%  
Interest coverage x1.713.1 13.1%   
Debt to equity ratio x0.60.1 726.1%  
Sales to assets ratio x0.40.8 54.4%   
Return on assets %4.16.4 63.6%  
Return on equity %2.98.9 32.1%  
Return on capital %6.910.8 64.1%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m15,69715,642 100.4%   
Fx outflow Rs m7354,884 15.1%   
Net fx Rs m14,96210,759 139.1%   
CASH FLOW
From Operations Rs m1,8713,411 54.8%  
From Investments Rs m5,826-1,354 -430.3%  
From Financial Activity Rs m-10,157-1,304 778.8%  
Net Cashflow Rs m-2,615753 -347.2%  

Share Holding

Indian Promoters % 27.7 45.9 60.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.4 331.6%  
FIIs % 8.6 25.3 34.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.4 148.9%  
Shareholders   56,241 36,892 152.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

IPCA LABS at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Dec 13, 2018 | Updated on Dec 13, 2018

IPCA LABS share price has hit a 52-week high. It is presently trading at Rs 824. BSE 500 Index is up by 0.7% at 14,435. Within the BSE 500, IPCA LABS (up 3.4%) and UJJIVAN FINANCIAL SERVICES (up 9.5%) are among the top gainers, while top losers are MANPASAND BEVERAGES and KWALITY DAIRY.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 13, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS